No­vo Nordisk and the fu­ture of obe­si­ty drugs; Ex­it Q&A with As­traZeneca’s Mene Pan­ga­los; Il­lu­mi­na’s bad week; Lay­offs sweep biotech; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With phar­ma earn­ings most­ly over, news may re­al­ly start to slow down next week. But if you’re stick­ing around, be sure to tune in for our in-depth fea­tures and orig­i­nal re­port­ing. Have a great week­end.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Source link

Related Articles

Back to top button